Compare APRE & YMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APRE | YMAT |
|---|---|---|
| Founded | 2006 | 1970 |
| Country | United States | Taiwan |
| Employees | N/A | 65 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Recreational Games/Products/Toys |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 7.3M |
| IPO Year | 2019 | N/A |
| Metric | APRE | YMAT |
|---|---|---|
| Price | $0.63 | $1.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.10 | N/A |
| AVG Volume (30 Days) | 57.0K | ★ 543.3K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.92 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.24 |
| 52 Week High | $1.93 | $6.45 |
| Indicator | APRE | YMAT |
|---|---|---|
| Relative Strength Index (RSI) | 40.85 | 56.82 |
| Support Level | $0.57 | $0.33 |
| Resistance Level | $0.83 | $2.47 |
| Average True Range (ATR) | 0.06 | 0.30 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 34.44 | 56.30 |
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
J-Star Holding Co Ltd is engaged in the research, development, and manufacturing of carbon fiber for a wide variety-of-products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products. The company has five segments: Bicycle frame, Racket, Crank, Service provision, and Others. The majority of its revenue is generated from the Bicycle frame segment. Geographically, the company operates in Taiwan, China, and other regions.